NCT02116803 - An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 28, 2014

Primary Completion Date

November 28, 2016

Study Completion Date

November 28, 2016

Conditions

Solid Tumors

Interventions

DRUG

dovitinib

Dovitinib was available in two formulations: capsules of 100 mg strength, and tablets of 100 mg strength and taken orally.

DRUG

fulvestrant

Fulvestrant is generally available as solution for injection in pre-filled syringes containing 250 mg of fulvestrant in 5 mL solution.

Trial Locations (9)

Novartis Investigative Site, Wilrijk

Novartis Investigative Site, Salzburg

Novartis Investigative Site, Torino

Novartis Investigative Site, Pavia

Novartis Investigative Site, Las Vegas

Novartis Investigative Site, The Bronx

Novartis Investigative Site, Copenhagen

Novartis Investigative Site, Osaka

Novartis Investigative Site, Palma de Mallorca